{"filing":{"accession_number":"0001171843-26-004488","cik":"0001745114","ticker":"MOLN","company_name":"MOLECULAR PARTNERS AG","form":"6-K","filing_date":"2026-07-06","report_date":null,"primary_document":"f6k_070626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1745114/000117184326004488/f6k_070626.htm"},"events":[{"id":16269,"run_id":14520,"accession_number":"0001171843-26-004488","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release discloses material clinical and pipeline progress across Molecular Partners' Radio-DARPin therapeutic program, including: ongoing Phase 1/2a dosing of MP0712 (DLL3-targeted, 212Pb-based) with initial data expected within months; initiation of compassionate care work in South Africa with MP0714 (225Ac-loaded DLL3 Radio-DARPin); planned first-in-human imaging for MP0726 (MSLN-targeted) in H2 2026; and two planned INDs in 2027. While not a discrete M\u0026A, financing, or governance event, these clinical milestones and pipeline expansions materially advance the company's drug development strategy and would affect a reasonable investor's assessment of near-term catalysts and long-term value creation.","company_name":"MOLECULAR PARTNERS AG","ticker":"MOLN","filing_date":"2026-07-06","form":"6-K","submitted_at":null,"items":[{"id":14320,"accession_number":"0001171843-26-004488","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release discloses material clinical and pipeline progress across Molecular Partners' Radio-DARPin therapeutic program, including: ongoing Phase 1/2a dosing of MP0712 (DLL3-targeted, 212Pb-based) with initial data expected within months; initiation of compassionate care work in South Africa with MP0714 (225Ac-loaded DLL3 Radio-DARPin); planned first-in-human imaging for MP0726 (MSLN-targeted) in H2 2026; and two planned INDs in 2027. While not a discrete M\u0026A, financing, or governance event, these clinical milestones and pipeline expansions materially advance the company's drug development strategy and would affect a reasonable investor's assessment of near-term catalysts and long-term value creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:02:04.445468+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14320,"accession_number":"0001171843-26-004488","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release discloses material clinical and pipeline progress across Molecular Partners' Radio-DARPin therapeutic program, including: ongoing Phase 1/2a dosing of MP0712 (DLL3-targeted, 212Pb-based) with initial data expected within months; initiation of compassionate care work in South Africa with MP0714 (225Ac-loaded DLL3 Radio-DARPin); planned first-in-human imaging for MP0726 (MSLN-targeted) in H2 2026; and two planned INDs in 2027. While not a discrete M\u0026A, financing, or governance event, these clinical milestones and pipeline expansions materially advance the company's drug development strategy and would affect a reasonable investor's assessment of near-term catalysts and long-term value creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:02:04.445468+00:00","company_name":"MOLECULAR PARTNERS AG","ticker":"MOLN","filing_date":"2026-07-06"}]}